Trillium Therapeutics Inc. To List Common Shares On The NASDAQ Capital Market Under The Symbol TRIL

TORONTO, Dec. 18, 2014 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium") (TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its common shares have been approved for listing on the NASDAQ Capital Market under the symbol "TRIL". Trading will commence on or around December 19. The Company will retain its listing on the Toronto Stock Exchange (TSX) under the symbol "TR".

"Secondary only to delivering on the fundamentals of our CD47 program, listing our shares on NASDAQ was a major corporate objective this year. We expect this will significantly diversify our investor pool, allowing larger funds to invest, leading to increased liquidity and shareholder value," commented Trillium's President and CEO, Dr. Niclas Stiernholm.

About Trillium Therapeutics:

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Forward looking information in this release includes our expectation of the benefits of listing on the NASDAQ Capital Market stock exchange. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: Trillium Therapeutics Inc. James Parsons Chief Financial Officer +1 416 595 0627 x232 james@trilliumtherapeutics.com www.trilliumtherapeutics.com

Help employers find you! Check out all the jobs and post your resume.